These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32840448)

  • 1. No Easy Answers in Allocating Unapproved COVID-19 Drugs Outside Clinical Trials.
    Webb J; Shah L; Lynch HF
    Am J Bioeth; 2020 Sep; 20(9):W1-W4. PubMed ID: 32840448
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
    Thomson K; Nachlis H
    JAMA; 2020 Oct; 324(13):1282-1283. PubMed ID: 32870235
    [No Abstract]   [Full Text] [Related]  

  • 3. An Ethical Framework for Allocating Scarce Inpatient Medications for COVID-19 in the US.
    DeJong C; Chen AH; Lo B
    JAMA; 2020 Jun; 323(23):2367-2368. PubMed ID: 32412580
    [No Abstract]   [Full Text] [Related]  

  • 4. Does hydroxychloroquine combat COVID-19? A timeline of evidence.
    Alia E; Grant-Kels JM
    J Am Acad Dermatol; 2020 Jul; 83(1):e33-e34. PubMed ID: 32283236
    [No Abstract]   [Full Text] [Related]  

  • 5. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
    Zhai MZ; Lye CT; Kesselheim AS
    JAMA Intern Med; 2020 Sep; 180(9):1145-1146. PubMed ID: 32427277
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug Evaluation during the Covid-19 Pandemic.
    Rome BN; Avorn J
    N Engl J Med; 2020 Jun; 382(24):2282-2284. PubMed ID: 32289216
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.
    Ison MG; Wolfe C; Boucher HW
    JAMA; 2020 Jun; 323(23):2365-2366. PubMed ID: 32407438
    [No Abstract]   [Full Text] [Related]  

  • 8. A Proposed Lottery System to Allocate Scarce COVID-19 Medications: Promoting Fairness and Generating Knowledge.
    White DB; Angus DC
    JAMA; 2020 Jul; 324(4):329-330. PubMed ID: 32579158
    [No Abstract]   [Full Text] [Related]  

  • 9. [Not Available].
    Nau JY
    Rev Med Suisse; 2020 Mar; 16(687):606-607. PubMed ID: 32216186
    [No Abstract]   [Full Text] [Related]  

  • 10. Databases for the targeted COVID-19 therapeutics.
    Wang Y; Li F; Zhang Y; Zhou Y; Tan Y; Chen Y; Zhu F
    Br J Pharmacol; 2020 Nov; 177(21):4999-5001. PubMed ID: 32845521
    [No Abstract]   [Full Text] [Related]  

  • 11. East meets West in COVID-19 therapeutics.
    Wang S; Zeng X; Wang Y; Zhao Y; Chen W; Chen YZ
    Pharmacol Res; 2020 Sep; 159():105008. PubMed ID: 32531323
    [No Abstract]   [Full Text] [Related]  

  • 12. A Review of Remdesivir for COVID-19: Data to Date.
    Mehta M; Shyh GI
    Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone nanomedicines for COVID-19.
    Lammers T; Sofias AM; van der Meel R; Schiffelers R; Storm G; Tacke F; Koschmieder S; Brümmendorf TH; Kiessling F; Metselaar JM
    Nat Nanotechnol; 2020 Aug; 15(8):622-624. PubMed ID: 32747742
    [No Abstract]   [Full Text] [Related]  

  • 14. BET 2: Hydroxychloroquine in the treatment of COVID-19.
    Howard L; Baombe J; Reynard C
    Emerg Med J; 2020 Jul; 37(7):451-453. PubMed ID: 32616659
    [No Abstract]   [Full Text] [Related]  

  • 15. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 16. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
    Wang Y; Chen L
    Br J Pharmacol; 2020 Nov; 177(21):4995-4996. PubMed ID: 32424836
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
    Gao J; Hu S
    Biosci Trends; 2020 May; 14(2):156-158. PubMed ID: 32281583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of nanomedicine on COVID-19 therapeutics.
    Mainardes RM; Diedrich C
    Ther Deliv; 2020 Jul; 11(7):411-414. PubMed ID: 32594863
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.
    Taccone FS; Gorham J; Vincent JL
    Lancet Respir Med; 2020 Jun; 8(6):539-541. PubMed ID: 32304640
    [No Abstract]   [Full Text] [Related]  

  • 20. Beat COVID-19 through innovation.
    Azoulay P; Jones B
    Science; 2020 May; 368(6491):553. PubMed ID: 32381693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.